Chardan notes that Allurion has announced additional data evaluating the use of its Allurion Balloon in combination with patients be treated with GLP1 therapy, which the analyst calls “intriguing,” especially the increase in lean body mass. However, the firm believes a more rigorous randomized controlled study will be needed to further validate this finding. Chardan has a Neutral rating and $2.50 price target on Allurion shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALUR:
- Allurion Technologies’ gastric balloon+GLP1s may become new SOC, says Roth MKM
- Allurion announces initial results from Allurion Program-GLP-1 combo
- Allurion Technologies price target lowered to $16 on split-adjusted basis
- Allurion Technologies announces issuance of new patents on weight loss device
- Allurion to sell 900,000 shares at $5.23 in registered direct offering
Questions or Comments about the article? Write to editor@tipranks.com